Short answer
Coherus Oncology, Inc. (CHRS) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $12M (up 62.0% year over year) with net income of −$38M.
Q1 2026 key financials · XBRL
- Revenue
- $12M
- +62.0% YoY
- Net income
- −$38M
- +32.2% YoY
- Operating margin
- -293.7%
- EPS (diluted)
- −$0.28
- +42.9% YoY
Source: XBRL data from the Coherus Oncology, Inc. (CHRS) Q1 2026 10-Q on SEC EDGAR. USD.
Coherus Oncology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $12.3M, up $4.7M YoY from $7.6M, driven by LOQTORZI volume growth
- LOQTORZI revenue $11.8M vs $7.3M YoY, the strongest performing product
- Gross margin 69% vs 65% YoY, with cost of goods sold $3.8M vs $2.7M
- R&D expense $21.5M vs $24.4M YoY, while SG&A declined to $23.1M from $26.0M
- Cash, equivalents and marketable securities $167.0M vs $172.1M at December 31, 2025; 2026 revenue expected higher than 2025
Risk Factors
- UDENYCA Sale removed the largest revenue contributor, potentially delaying profitability as LOQTORZI faces chemotherapy and off-label immunotherapy competition
- Accumulated deficit $1.4 billion as of March 31, 2026, with continued losses possible from LOQTORZI development and pipeline programs
- Cash, cash equivalents and marketable securities $167.0 million, creating ongoing dependence on additional financing
- LOQTORZI and future products face ongoing FDA scrutiny, including cGMP inspections, post-marketing obligations and potential recalls
- LOQTORZI coverage and reimbursement remain uncertain, with IRA-driven pricing pressure potentially limiting market access and revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Coherus Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.